For decades, immunologists have explored CAR-T cell therapy as an effective tool to fight blood cancer. Increasingly, CAR-T cells are being explored as a potential silver bullet for treating autoimmune diseases, like lupus—which currently have no cure.
Thus far, CAR-T cell therapy has largely used CRISPR-modified immune cells from a person to treat that person’s own diseases. But new research from China has made a huge step forward for this treatment: Researchers were successful in using donated CAR-T cells from one person to treat another person’s systemic sclerosis, an autoimmune condition that causes atypical growth of connective tissues.
If donor CAR-T cell therapy does indeed work, as posited in this paper, it could mean the therapy is more scalable than it would be otherwise. Joining Ira to talk about this study and its potential impact is Daniel Baker, PhD student in the immunology lab of Dr. Carl June at the University of Pennsylvania.
Further Reading
- Read how CAR-T cell therapy shows promise for lupus treatment via The Atlantic.
Donate To Science Friday
Invest in quality science journalism by making a donation to Science Friday.
Segment Guests
Daniel Baker
Daniel Baker is a PhD student in Immunology at the University of Pennsylvania in Philadelphia, Pennsylvania.
Segment Transcript
The transcript of this segment is being processed. It will be available within one week after the show airs.
Meet the Producers and Host
About Kathleen Davis
@katjacquelineKathleen Davis is a producer and fill-in host at Science Friday, which means she spends her weeks researching, writing, editing, and sometimes talking into a microphone. She’s always eager to talk about freshwater lakes and Coney Island diners.
About Ira Flatow
@iraflatowIra Flatow is the host and executive producer of Science Friday. His green thumb has revived many an office plant at death’s door.